These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 21607858)

  • 41. G-protein-coupled receptor allosterism: the promise and the problem(s).
    Christopoulos A; May LT; Avlani VA; Sexton PM
    Biochem Soc Trans; 2004 Nov; 32(Pt 5):873-7. PubMed ID: 15494038
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Muscarinic allosteric enhancers of ligand binding: pivotal pharmacophoric elements in hexamethonio-type agents.
    Muth M; Sennwitz M; Mohr K; Holzgrabe U
    J Med Chem; 2005 Mar; 48(6):2212-7. PubMed ID: 15771463
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Determination of allosteric interactions using radioligand-binding techniques.
    Lazareno S
    Methods Mol Biol; 2004; 259():29-46. PubMed ID: 15250484
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Design, synthesis, and action of oxotremorine-related hybrid-type allosteric modulators of muscarinic acetylcholine receptors.
    Disingrini T; Muth M; Dallanoce C; Barocelli E; Bertoni S; Kellershohn K; Mohr K; De Amici M; Holzgrabe U
    J Med Chem; 2006 Jan; 49(1):366-72. PubMed ID: 16392821
    [TBL] [Abstract][Full Text] [Related]  

  • 45. When simple agonism is not enough: emerging modalities of GPCR ligands.
    Smith NJ; Bennett KA; Milligan G
    Mol Cell Endocrinol; 2011 Jan; 331(2):241-7. PubMed ID: 20654693
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Competition between positive and negative allosteric effectors on muscarinic receptors.
    Proska J; Tucek S
    Mol Pharmacol; 1995 Oct; 48(4):696-702. PubMed ID: 7476896
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain.
    O'Brien JA; Lemaire W; Wittmann M; Jacobson MA; Ha SN; Wisnoski DD; Lindsley CW; Schaffhauser HJ; Rowe B; Sur C; Duggan ME; Pettibone DJ; Conn PJ; Williams DL
    J Pharmacol Exp Ther; 2004 May; 309(2):568-77. PubMed ID: 14747613
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Allosteric modulators of G-protein-coupled receptors.
    May LT; Christopoulos A
    Curr Opin Pharmacol; 2003 Oct; 3(5):551-6. PubMed ID: 14559102
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A simple method to detect allostery in GPCR dimers.
    Goupil E; Laporte SA; Hébert TE
    Methods Cell Biol; 2013; 117():165-79. PubMed ID: 24143977
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Allosteric modulation of G protein-coupled receptors.
    May LT; Avlani VA; Sexton PM; Christopoulos A
    Curr Pharm Des; 2004; 10(17):2003-13. PubMed ID: 15279541
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Repositioning Dequalinium as Potent Muscarinic Allosteric Ligand by Combining Virtual Screening Campaigns and Experimental Binding Assays.
    Mazzolari A; Gervasoni S; Pedretti A; Fumagalli L; Matucci R; Vistoli G
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825082
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The best of both worlds? Bitopic orthosteric/allosteric ligands of g protein-coupled receptors.
    Valant C; Robert Lane J; Sexton PM; Christopoulos A
    Annu Rev Pharmacol Toxicol; 2012; 52():153-78. PubMed ID: 21910627
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synthesis and application of the first radioligand targeting the allosteric binding pocket of chemokine receptor CXCR3.
    Bernat V; Heinrich MR; Baumeister P; Buschauer A; Tschammer N
    ChemMedChem; 2012 Aug; 7(8):1481-9. PubMed ID: 22689503
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Muscarinic receptor subclasses: allosteric interactions.
    Birdsall NJ; Hulme EC; Stockton JM
    Cold Spring Harb Symp Quant Biol; 1983; 48 Pt 1():53-6. PubMed ID: 6586362
    [No Abstract]   [Full Text] [Related]  

  • 55. G protein-coupled receptor allosterism and complexing.
    Christopoulos A; Kenakin T
    Pharmacol Rev; 2002 Jun; 54(2):323-74. PubMed ID: 12037145
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Quantitative analysis of receptor allosterism and its implication for drug discovery.
    Zhang R; Kavana M
    Expert Opin Drug Discov; 2015 Jul; 10(7):763-80. PubMed ID: 25927503
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Allosteric drugs acting at muscarinic acetylcholine receptors.
    Waelbroeck M
    Neurochem Res; 2003 Apr; 28(3-4):419-22. PubMed ID: 12675125
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Radioligand dissociation measurements: potential interference of rebinding and allosteric mechanisms and physiological relevance of the biological model systems.
    Vauquelin G; Van Liefde I
    Expert Opin Drug Discov; 2012 Jul; 7(7):583-95. PubMed ID: 22650795
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Toward understanding the molecular basis for chemical allosteric modulator design.
    Wang Q; Zheng M; Huang Z; Liu X; Zhou H; Chen Y; Shi T; Zhang J
    J Mol Graph Model; 2012 Sep; 38():324-33. PubMed ID: 23085171
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PAM-Antagonists: A Better Way to Block Pathological Receptor Signaling?
    Kenakin T; Strachan RT
    Trends Pharmacol Sci; 2018 Aug; 39(8):748-765. PubMed ID: 29885909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.